DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
SAN FRANCISCO, Jan. 27, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Mallinckrodt PLC (NYSE:MNK) to the securities class action lawsuit filed in the U.S. District Court for the District of Columbia and the March 27, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of MNK between November 25, 2014 and January 18, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MNK
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Beginning in late 2014, MNK allegedly made assurances to investors that its drug, Acthar, produces sustainable revenues that were mostly attributable to sources other than Medicare and Medicaid.
However, on November 16, 2016, a Citron Research report revealed that the percentage of Acthar 2014 and 2015 revenues attributable to Medicare alone was over 45% and 48%, respectively. Citron also reported that the total percentage of Acthar 2014 and 2015 revenues attributable to both Medicare and Medicaid was over 60% and 61%, respectively. This news drove the price of MNK shares down over 18%.
Then, on January 18, 2017, the U.S. Federal Trade Commission announced that MNK would pay $100 million to settle charges that Acthar revenues were the product of an illegal monopoly. This news drove the price of MNK down over 5%.
“We’re evaluating management’s knowledge of facts undermining the Defendants’ assurances to investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MNK should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
